ScaleReady’s Post

Decentralized cell therapy production sounds great, but it's riddled with complexities. Get an in-depth look at handling scalability, digital solutions, and more in a Phacilitate panel. Josh Ludwig discusses the path to GMP success leveraging Wilson Wolf Manufacturing, LLC, Bio-Techne and Fresenius Kabi products. https://lnkd.in/eZca_ZYD #celltherapymanufacturing #celltherapy

Navigate the landscape of cell therapies manufacturing with 'Open or Closed Manufacturing for Cell Therapies' on The Medicine Maker. Explore the critical considerations and innovations shaping the future of this dynamic field. Stay informed, stay ahead! #CellTherapies #Manufacturing #TheMedicineMaker https://bit.ly/3UtVzR9

“Manufacturing capacity was an important topic of conversation throughout the event. “When we talk about CAR-T, the approved products are all autologous products,” says English, “so we’re in this paradigm of one lot per patient, and that will always throttle the pace at which material can be produced, released, and then delivered to patients.” Allogeneic CAR-T cell therapies are a promising avenue the industry is exploring to overcome the challenge of limited manufacturing capacity. And while allogeneic CAR-T therapies represent a growing segment in the CGT space, they haven’t yet demonstrated better efficacy than their autologous counterparts — nor have any been approved. “Thus, the effort to improve autologous CAR-T manufacturing continues along two primary fronts: shortening the manufacturing process (and consequently, vein-to-vein time) and scaling manufacturing capacity to produce more lots simultaneously.

New on Pharma's Almanac: Cell X Technologies' Karen Weisinger discusses the promise of cell therapy, the challenges to overcome to realize that potential, and the role that the Celligent system in maximizing consistency in cell processes as they scale. #biopharms #celltherapy #cellprocessing #technology #automation

This blog explores how qPCR-based testing solutions can address challenges in product purity and safety through mycoplasma and sterility testing, and environmental monitoring in cell therapy manufacturing

Another interesting article discussing Kite Pharma's path to automating manual aspects of cell therapy manufacturing. The possibilities of reducing cost for patients, speeding up manufacturing, and making it scalable are exciting. I can't wait to see where innovation takes us! #Cytiva #CellTherapy #Sefia

🔬 Delve into the vital role of cell counting amidst the rapid expansion of advanced therapies! 🌟 Our latest article explores why precise cell counting is becoming increasingly indispensable in the realm of advanced therapies. #Bioprocessing #AdvancedTherapies #CellCounting" Check it out here: https://lnkd.in/gZ9fCpfG

Recent studies have highlighted novel T cell manufacturing platforms and processes with a shortened ex-vivo expansion step reduces overall time to manufacture, while producing CAR-T cells that have improved anti-tumor activity in preclinical and early clinical settings ( 6 – 8 )

Did you miss our recent article on streamlining #celltherapy quality control with cell mimics? Check it out to see how Slingshot Biosciences is helping to standardize #flowcytometry and #celltherapy with innovative, scalable cell mimics. We’d love to hear your thoughts and experiences—join the conversation by leaving a comment below!

Unlocking the Potential of Cell Therapy: Addressing the Key Bottlenecks in Supply Chains. Learn how Excellos is pioneering solutions to enhance material sourcing, logistics, and manufacturing capacity in the dynamic field of cell therapy in our new blog. #CellTherapy #SupplyChain #Innovation